HIV Disease Coverage Forecast and Market Analysis to 2024, Pharma Intelligence
NEW YORK, June 4, 2019 /PRNewswire/ --
Disease Overview
The human immunodeficiency virus, or HIV, is a retrovirus that infects the cells of the immune system such as T lymphocytes, specifically cluster of differentiation-4+ T cells, dendritic cells, and macrophages. Infection leads to a progressive weakening of the immune system and ultimately results in acquired immunodeficiency syndrome (AIDS).
Read the full report: https://www.reportlinker.com/p05780136/?utm_source=PRN
Market Snapshot
B/F/TAF will drive significant revenue growth due to its attractive combination of an INSTI and a preferred backbone.
TAF-based regimens are rapidly cannibalizing the share of TDF-based products due to superior renal and bone safety.
HIV prevalence is increasing in the analyzed markets as people are living longer on antiretroviral therapy.
Rapid uptake of TAF-based regimens in the US will protect Gilead's revenues following TDF patent expiry.
B/F/TAF's potency and clean tolerability profile will outcompete its rivals, restricting their uptake at launch.
Read the full report: https://www.reportlinker.com/p05780136/?utm_source=PRN
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article